Monte Rosa Therapeutics (GLUE) Receivables - Other (2023 - 2025)
Historic Receivables - Other for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $5.0 million.
- Monte Rosa Therapeutics' Receivables - Other rose 73445.38% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 73445.38%. This contributed to the annual value of $173000.0 for FY2024, which is 6574.26% down from last year.
- According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Receivables - Other is $5.0 million, which was up 73445.38% from $2.4 million recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' Receivables - Other registered a high of $5.0 million during Q3 2025, and its lowest value of $173000.0 during Q4 2024.
- Over the past 3 years, Monte Rosa Therapeutics' median Receivables - Other value was $842000.0 (recorded in 2024), while the average stood at $1.4 million.
- In the last 5 years, Monte Rosa Therapeutics' Receivables - Other crashed by 7230.41% in 2024 and then skyrocketed by 73445.38% in 2025.
- Over the past 3 years, Monte Rosa Therapeutics' Receivables - Other (Quarter) stood at $505000.0 in 2023, then plummeted by 65.74% to $173000.0 in 2024, then soared by 2769.94% to $5.0 million in 2025.
- Its Receivables - Other was $5.0 million in Q3 2025, compared to $2.4 million in Q2 2025 and $1.4 million in Q1 2025.